Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 321 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Fructose Fuels Cancer Growth Indirectly, Lab Study Finds January 14, 2025 Age and Frailty Should Be Considered Independently When Evaluating Potential Risk... June 27, 2022 Breast Cancer Patients With Anxiety or Depression More Prone to Opioid... August 27, 2019 Living With Metastatic Breast Cancer: How I Reinvented Myself October 30, 2020 Load more HOT NEWS Cancer in Lymph Nodes May Help Tumors Spread by Enlisting Immune... Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate... ESMO Recommendations on Cancer Care Reflected in Un ECOSOC Ministerial Declaration... Spending Review 2020 – Steps in the right direction, but opportunities...
